Laurus Labs Limited
Laurus Labs Limited is a Hyderabad-based pharmaceutical company established in 2005. It develops and manufactures Active Pharmaceutical Ingredients (APIs), generic formulations, biotechnology products, and provides CDMO services. The company is recognized globally for its leadership in anti-retroviral APIs used in HIV treatment. With a strong focus on research, innovation, and quality, Laurus Labs serves customers across numerous countries and contributes to improving access to affordable healthcare worldwide.
Business Segments
Segment Revenue Contribution (%)
The major business segments of Laurus Labs Limited and their approximate revenue contribution for FY2025-26 are:
- SegmentRevenue Contribution (%)
- CDMO (Contract Development & Manufacturing): 36%
- FDF (Finished Dosage Forms): 34%
- APIs (Active Pharmaceutical Ingredients): 26%
- Synthesis: 3%
- Others: 1%
Shareholding Pattern (March 2026)
Financial Summary
| Particulars | Mar-2024 | Mar-2025 | Mar-2026 |
| Sales | 5,041 | 5,554 | 6,813 |
| Sales Growth % | -16.55% | 10.18% | 22.67% |
| Expenses | 4,261 | 4,499 | 5,028 |
| Operating Profit | 779 | 1,055 | 1,785 |
| OPM % | 15% | 19% | 26% |
| Net Profit | 162 | 358 | 890 |
| EPS in Rs | 2.98 | 6.64 | 16.46 |
Synopsis of Financials
Synopsis of Results (FY26)
- Revenue: ₹6,813 crore (↑23% YoY)
- EBITDA: ₹1,826 crore (↑64% YoY)
- EBITDA Margin: 26.8%
- PBT: ₹1,182 crore (↑144% YoY)
- PAT: ₹889 crore (↑148% YoY)
- ROCE: 17.7%
Laurus Labs delivered an excellent FY2025-26 performance with strong revenue growth, significant margin expansion, and higher profitability, driven by robust CDMO demand, operational efficiency, and an improved product mix.
Final Outlook
Laurus Labs Limited delivered a strong turnaround in FY2025-26, demonstrating robust execution across its core business segments and reinforcing its long-term growth potential. The company reported revenue from operations of ₹6,813 crore, reflecting a 23% YoY increase, while EBITDA grew 64% YoY to ₹1,826 crore, resulting in a healthy EBITDA margin of 26.8%. Profit Before Tax (PBT) more than doubled to ₹1,182 crore, and Profit After Tax (PAT) surged 148% YoY to ₹889 crore, highlighting significant improvement in operational efficiency and profitability. These results were driven by strong performance in the CDMO business, improved product mix, higher capacity utilization, and disciplined cost management.
Looking ahead, Laurus Labs is strategically positioned to capitalize on the growing global demand for outsourced pharmaceutical manufacturing, complex generic formulations, and biotechnology services. The company continues to expand its Contract Development and Manufacturing Organization (CDMO) capabilities, which are expected to remain a key growth driver due to increasing outsourcing by global pharmaceutical and biotechnology companies. In addition, continued investments in advanced manufacturing technologies, research & development, and capacity expansion are expected to strengthen its competitive position and support the commercialization of high-value products.
The company’s diversified business model across APIs, Finished Dosage Forms (FDF), CDMO, and biotechnology reduces dependence on any single business segment while providing multiple growth avenues. Laurus Labs is also focused on increasing its presence in regulated markets such as the United States, Europe, and other global markets, supported by strong regulatory compliance and long-standing customer relationships. The growing contribution from specialty products and innovation-driven businesses is expected to improve margins and enhance earnings quality over the medium to long term.
From an investment perspective, Laurus Labs offers an attractive long-term growth story supported by a strong balance sheet, improving return ratios, healthy operating cash flows, and a scalable business model. The company’s strategic investments in high-growth segments, expanding global customer base, and focus on operational excellence are likely to drive sustainable revenue growth and profitability over the next few years. While regulatory compliance, pricing pressure, and raw material cost fluctuations remain key risks, the company’s diversified portfolio, execution capabilities, and strong industry positioning provide confidence in its long-term prospects. Overall, Laurus Labs remains well positioned to deliver consistent earnings growth and create sustainable shareholder value, making it a compelling long-term investment opportunity in the Indian pharmaceutical and CDMO sector.
